1. Home
  2. CYTK vs HQY Comparison

CYTK vs HQY Comparison

Compare CYTK & HQY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • HQY
  • Stock Information
  • Founded
  • CYTK 1997
  • HQY 2002
  • Country
  • CYTK United States
  • HQY United States
  • Employees
  • CYTK N/A
  • HQY N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • HQY Business Services
  • Sector
  • CYTK Health Care
  • HQY Consumer Discretionary
  • Exchange
  • CYTK Nasdaq
  • HQY Nasdaq
  • Market Cap
  • CYTK 6.0B
  • HQY 8.5B
  • IPO Year
  • CYTK 2004
  • HQY 2014
  • Fundamental
  • Price
  • CYTK $48.87
  • HQY $94.95
  • Analyst Decision
  • CYTK Buy
  • HQY Buy
  • Analyst Count
  • CYTK 16
  • HQY 13
  • Target Price
  • CYTK $84.07
  • HQY $111.23
  • AVG Volume (30 Days)
  • CYTK 1.1M
  • HQY 867.5K
  • Earning Date
  • CYTK 11-06-2024
  • HQY 12-09-2024
  • Dividend Yield
  • CYTK N/A
  • HQY N/A
  • EPS Growth
  • CYTK N/A
  • HQY 218.51
  • EPS
  • CYTK N/A
  • HQY 1.09
  • Revenue
  • CYTK $3,219,000.00
  • HQY $1,150,344,000.00
  • Revenue This Year
  • CYTK N/A
  • HQY $19.55
  • Revenue Next Year
  • CYTK $795.25
  • HQY $11.21
  • P/E Ratio
  • CYTK N/A
  • HQY $87.26
  • Revenue Growth
  • CYTK N/A
  • HQY 18.47
  • 52 Week Low
  • CYTK $43.21
  • HQY $64.62
  • 52 Week High
  • CYTK $110.25
  • HQY $105.82
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 44.62
  • HQY 46.56
  • Support Level
  • CYTK $45.66
  • HQY $90.34
  • Resistance Level
  • CYTK $49.40
  • HQY $98.24
  • Average True Range (ATR)
  • CYTK 1.71
  • HQY 3.20
  • MACD
  • CYTK -0.20
  • HQY -1.07
  • Stochastic Oscillator
  • CYTK 50.79
  • HQY 32.79

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About HQY HealthEquity Inc.

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Share on Social Networks: